Mathieu Martin |

Espace MicroCaps 5to7 Cocktail – Life Sciences Special

Espace MicroCaps is glad to invite you to its thematic 5to7 cocktail about life sciences, at the Bier Markt Montreal on Tuesday, May 22nd at 5:00pm. Our events are the perfect occasion to improve your investing skills, discover new investment opportunities in the Canadian microcap space and network with likeminded investors.

The event will showcase three companies from the healthcare and biotech sectors: BELLUS Health (TSX:BLU), Devonian Health Group (TSX Venture:GSD) and Microbix Biosystems (TSX:MBX). The first two are based in Quebec while the third one’s CEO grew up in Montreal. We are very happy to be able to showcase and support local companies in our events! Please note that some presentations might be in French.

Where: Bier Markt Montreal, 1221 René-Lévesque W, Montreal

When: Tuesday, May 22nd from 5:00pm to 7:00pm

Cost: 5$ / All of the ticket sales proceeds will be given to Prosper Canada, a national charity dedicated to expanding economic opportunity for Canadians living in poverty through program and policy innovation.

The first 75 participants to register and to show up at the event before 5:30pm will receive a 10$ coupon for a free drink of their choice. No coupons will be given after 5:30pm. A poutine bar will be offered to all attendees and appetizers will be served during the cocktail as well.

To reserve your spot: Eventbrite – Espace MicroCaps 5to7 Cocktail – Life Sciences Special

The presenting companies have been hand-picked based on the attractiveness of their business model, market opportunity and fundamentals.



About: BELLUS is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company’s lead drug candidate BLU‐5937 for chronic cough and several other partnered clinical‐stage drug development programs. BLU‐5937, a selective P2X3 antagonist, has the potential to be a best‐in‐class therapeutic for chronic cough patients who do not respond to current therapies.

Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life widely. A recent commercial assessment performed by Torreya Insights on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.


Devonian Health Group (TSX Venture : GSD)

About:  Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX).

While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.


Microbix Biosystems (TSX : MBX)

About: Microbix is a leading independent producer of bacterial and viral antigens for use in medical diagnostics and laboratory quality assessment processes, selling over 100 commercial products to many international diagnostics makers or laboratory accreditation organizations. Antigens enable the detection of circulating immune system antibodies – needed to establish whether a patient has been exposed to a pathogen, has adequate immunity to it, or may have an active infection. The need for antigens is increasing as immunoassay diagnostics are being adopted more broadly, particularly into Asia-Pacific nations.


We are glad to organize a life sciences special for a second year in a row. Investing in this sector is not without risks, but those who are successful can generate exceptional returns. We are very excited to showcase three companies that we feel have a bright future, and we hope you’ll enjoy! Again, to book a ticket, please click here.

We hope to see many of you on May 22nd!

Philippe and Mathieu



Espace MicroCaps is under contract with Rivemont Investments (“Rivemont”) to provide securities and strategy analysis for the Rivemont MicroCap Fund (the “Fund”). In other words, Espace MicroCaps acts as external expert/consultant for the Fund. In return for this expertise, Espace MicroCaps is remunerated by Rivemont.

Decisions as to whether or not to trade a security for the Fund are made exclusively by Rivemont.

For full disclosure and transparency, regarding the companies that will present at our 5to7 Cocktail – Life Sciences Special or that were mentioned in this article:

  • The Fund holds no securities of BELLUS Health (BLU.TO), Devonian Health Group (GSD.V) and Microbix Biosystems (MBX.TO). Although the Fund does not hold any securities of these companies as of today, the Fund may acquire these securities in the future.
  • Mathieu and Philippe hold warrants of Microbix Biosystems (MBX.TO) with an exercise price of $0.55 and valid until October 13th, 2020.

The main objective of the 5to7 Cocktail events that we hold on a regular basis is to allow very small companies to present their products and services and to tell their story to a new investing public.

Each company that will present at the event will pay Espace MicroCaps an amount of $2,000 + taxes. This amount is used to cover the cost of drinks and hors d’oeuvres offered during the meeting and to compensate Espace MicroCaps for the efforts related to the organization of the meeting.

Company presentations are neither an offer to sell nor a solicitation of an offer to purchase securities and should not be considered legal, tax, financial or investment advice.

Espace MicroCaps is not responsible for direct or indirect trading losses caused by the information presented by companies at the event. Everyone is advised to make their own analyzes and inquiries and to consult their own professional advisers with respect to legal, tax, accounting and other matters relating to the acquisition, holding or disposition of an investment.